newsfilter
← Latest News
GlobeNewswire·

Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

  • Polyrizon Ltd. (NASDAQ: PLRZ) announced the successful production of a Good Manufacturing Practice (GMP) batch of clinical trial material (CTM) for its lead product candidate.
  • The manufacturing was executed in collaboration with Eurofins CDMO AmatsiAquitaine S.A.S. under an existing agreement to support the company's clinical development program.
  • This milestone follows two prior development batches that demonstrated batch-to-batch consistency & product stability, confirming the robustness of the manufacturing process.
  • The GMP batch will be utilized to support upcoming clinical activities & regulatory submissions for a planned U.S. clinical study scheduled later in 2026.
  • CEO Tomer Izraeli stated the milestone advances the clinical strategy & reflects the company's commitment to developing intranasal solutions designed to protect against airborne allergens & viruses.
  • Polyrizon specializes in hydrogel nasal sprays using its proprietary Capture & Contain (C&C) technology to form a protective barrier in the nasal cavity.
  • The company is further developing C&C technology for improved bioadhesion & retention while advancing a pre-clinical "Trap & Target" (T&T) technology for intranasal drug delivery.